Takeda Pharmaceutical Company Limited

Tokyo Medical and Dental University

Yusuke Adachi

Tetsuya Nagata

Takanori Yokota

Taiji Asami

Hideki Furukawa

Shigekazu Sasaki

Naoki Nishizawa

Ayumu Niida

Tomohiro Seki

Kosuke Hidaka

Takatoshi Yogo

Yasuo Nakagawa

Kenichi Miyata

Ryosuke Tokunoh

Naoto Arimura

The object of the present invention is to provide a nucleic acid agent that can be efficiently delivered to the nervous system, particularly the central nervous system to which the BBB mechanism prevents drug delivery, and can produce an antisense effect on a target transcriptional product at the delivered site, and a composition comprising the same. Provided is a double-stranded nucleic acid complex formed by annealing a first nucleic acid strand capable of hybridizing to part of a target transcriptional product, and has an antisense effect on the target transcriptional product, to a second nucleic acid strand comprising a base sequence complementary to the first nucleic acid strand, and is bound to tocopherol or an analog thereof, cholesterol or an analog thereof, or a substituted or unsubstituted Calkyl group, a substituted or unsubstituted Calkenyl group, or a substituted or unsubstituted Calkoxy group.

BBB-crossing lipid ligand of hetero nucleic acid

The present invention aims to provide a peptide having a superior Y2 receptor agonist action and useful as an agent for the prophylaxis or treatment of obesity and the like. A peptide represented by the formula:P&#x2014;X-A25-A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-NHwherein each symbol is as described in the specification, or a salt thereof.

Peptide and use thereof

Growing community of inventors

Kanagawa, Japan

Yusuke Adachi